STOCK TITAN

eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

eXoZymes (EXOZ) reported a third-quarter net loss of $2.24 million and gave an update on manufacturing preparations for its lead supplement. The quarterly loss included a $0.77 million non-cash gain from a change in the value of warrant liabilities. Net loss was $7.49 million for the nine months ended September 30, 2026. Quarterly operating expenses rose to $3.05 million from $2.52 million a year earlier. The company ended the quarter with $3.26 million in cash and cash equivalents, which it expects to fund operations through the beginning of 2027.

Technology transfer to Curia began in Q4 2026 to support planned larger-scale manufacturing in 2027 for NCT, the ingredient behind Tyferyn. Two additional supplement candidates completed proof of concept, an early step in development. One, SAPPHIRE, has begun work to increase production scale.

Loading...
Loading translation...
4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointNCT manufacturing preparations advanced as technology transfer to Curia began in Q4 2026 to support larger-scale manufacturing in 2027
  • Minor pointTwo supplement candidates, SAPPHIRE and AMETHYST, completed proof of concept
  • Minor pointSAPPHIRE scale-up began after the candidate completed proof of concept
  • Minor pointNon-cash gain of $0.77 million from revaluing warrant liabilities reduced the reported quarterly net loss

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash and cash equivalents of $3.26 million at quarter-end are expected to fund operations through the beginning of 2027
  • Moderate pointNet loss was $2.24 million for the quarter and $7.49 million for the nine months ended September 30, 2026
  • Moderate pointOperating expenses rose to $3.05 million in Q3 2026 from $2.52 million a year earlier

Key Figures

Operating expenses: $3.05 million Net loss: $2.24 million Net loss: $7.49 million +2 more
Operating expenses
$3.05 million
Q3 2026; compared with $2.52 million in Q3 2025
Net loss
$2.24 million
Third quarter 2026
Net loss
$7.49 million
Nine months ended September 30, 2026
Cash and cash equivalents
$3.26 million
At quarter-end; expected to support operations through the beginning of 2027
Non-cash warrant-liability gain
$0.77 million
Included in third-quarter net loss

Previous Earnings Reports

1 past event · Latest: Aug 20
Same Type 1 event
  1. Aug 20

    Q2 earnings

    24h Move
    +1.6%

    Q2 report cited higher NCT productivity, financing, grant funding and $5.65 million cash.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

technology transfer, proof of concept, fair value, warrant liabilities
4 terms
technology transfer technical
"Technology transfer began in the fourth quarter of 2026"
Technology transfer is the process of moving an invention, know‑how, or technical capability from one organization to another so it can be developed, manufactured or sold. For investors it matters because successful transfers turn research or prototypes into marketable products or revenue streams—similar to handing a recipe and kitchen to someone who can scale it up—and they affect a company’s growth prospects, costs, timelines and competitive position.
proof of concept technical
"advanced two additional supplement candidates through proof of concept"
A proof of concept is a demonstration that shows a new idea, product, or method is feasible and can work as intended. It serves as evidence that an approach has potential value before full development or investment begins. For investors, it helps assess the likelihood of success and reduces uncertainty about whether the concept can deliver its promised benefits.
fair value financial
"gain from the change in fair value of warrant liabilities"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
View in glossary
warrant liabilities financial
"change in fair value of warrant liabilities"
Warrant liabilities are the financial obligations a company records when it grants warrants—special rights allowing someone to buy shares at a set price in the future. If the warrants are expected to be exercised, they are treated as a liability because the company might need to deliver shares or cash later. This matters to investors because it affects the company’s reported financial health and the potential dilution of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LOS ANGELES, CA / ACCESS Newswire / November 19, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar at 5:00 PM Eastern Time to discuss results for the third quarter ended September 30, 2026, and provide an update on recent business developments.

Michael Heltzen, CEO of eXoZymes, states, "We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart."

Third quarter highlights

  • Commercial manufacturing preparations underway with Curia: In September, eXoZymes selected Curia as its commercial-scale manufacturing partner for NCT, the rare natural molecule behind its lead supplement brand, Tyferyn. Technology transfer began in the fourth quarter of 2026, with the collaboration intended to support larger-scale manufacturing in 2027, representing an important step toward commercial readiness.
  • Tyferyn introduced as the brand for human use: eXoZymes introduced Tyferyn as the new brand name for its lead nutraceutical ingredient focused on human wellness applications. The rebranding establishes a distinctive, consumer-friendly identity as the Company advances preparations for commercialization.
  • Product pipeline expands: eXoZymes has advanced two additional supplement candidates through proof of concept, demonstrating the broader potential of its cell-free biomanufacturing platform. Product SAPPHIRE, targeting joint comfort, has begun scale-up activities, while Product AMETHYST, targeting mental stress, focus and energy, has also completed proof of concept. The programs support the Company's strategy of building a diversified portfolio of high-value products using its shared enzyme technology and development capabilities.
  • Operational and financial update: Operating expenses for the third quarter of 2026 were $3.05 million, compared with $2.52 million for the same period in 2025. Net loss was $2.24 million for the quarter and $7.49 million for the nine months ended September 30, 2026. Net loss for the quarter includes a $0.77 million non-cash gain from the change in fair value of warrant liabilities. The Company ended the quarter with $3.26 million in cash and cash equivalents, which the Company expects will support operations through the beginning of 2027.

Investors and interested parties can access the live webinar through eXoZymes' investor relations website at:
https://video.exozymes.com/exoz-investor-update-3q26-nov-19

Michael Heltzen, CEO of eXoZymes, will lead the call and be joined by select members of the management team to review recent developments and ongoing initiatives. A recording and transcript of the conference call will also be made publicly available following the event.

About eXoZymes
Founded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable natural products and new analogs outside living cells. The company's platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.

eXoZymes is building a portfolio of biosolutions across NCT - now Tyferyn for human use - cannabinoid analogs, santalene, and other high-value natural product molecules, with potential commercialization paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
press@exozymes.com
LinkedIn | X | YouTube

SOURCE: eXoZymes



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long does eXoZymes expect its third-quarter 2026 cash balance to fund operations?

eXoZymes expects its $3.26 million in quarter-end cash and cash equivalents to fund operations through the beginning of 2027.

What is Curia's role in manufacturing the ingredient behind eXoZymes' Tyferyn?

Curia is the commercial-scale manufacturing partner for NCT, the ingredient behind Tyferyn. eXoZymes selected Curia in September, and technology transfer began in the fourth quarter of 2026 to support larger-scale manufacturing in 2027.

What are eXoZymes' SAPPHIRE and AMETHYST supplement candidates intended to address?

SAPPHIRE targets joint comfort, while AMETHYST targets mental stress, focus and energy.

Keep reading